Market Overview

UPDATE: Goldman Sachs Reinstates Neutral on BioMed Realty as Acquisitions Broaden Their Portfolio

Share:
Related BMR
Stick Another 'Pin' Into San Francisco's Red-Hot Office Development Map
One Of The Market's Biggest Healthcare REITs: Should You Buy?
4 REIT Gems That Mr. Market Is Ignoring (Seeking Alpha)

In a report published on Friday, Goldman Sachs analyst Matthew Rand reinstated a Neutral rating on BioMed Realty (NYSE: BMR) and maintained its $21 price target on the company.

In the report, Goldman Sachs commented that, "We have removed the Not Rated designation from BioMed Realty shares. We rate BMR as a Neutral, with a 12-month, $21 price target. We continue to think that BMR's most relevant comp is Alexandria Real Estate Equities (ARE), which we also rate Neutral. In addition, we think that Digital Realty Trust (DLR, Buy) offers better value as well as better growth within the more capital-intensive, slow-growth property sectors."

BioMed Realty closed on Thursday at $20.50

Latest Ratings for BMR

DateFirmActionFromTo
Jul 2015JefferiesMaintainsHold
Jun 2015Raymond JamesMaintainsOutperform
May 2015BairdMaintainsOutperform

View More Analyst Ratings for BMR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Matthew RandAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BMR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters